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Recent years have witnessed much progress in both basic research and clinical trials regarding cancer
immunotherapy with chimeric antigen receptor (CAR)-engineered T cells. The unique structure of CAR endows
T cell tumor specific cytotoxicity and resistance to immunosuppressive microenvironment in cancers, which helps
patients to better tackle the issue of immunological tolerance. Adoptive immunotherapy (AIT) using this
supernatural T cell have gained momentum after decades of intense debates because of the promising results
obtained from preclinical models and clinical trials. However, it is very important for us to evaluate thoroughly
the challenges/obstacles before widespread clinical application, which clearly warrants more studies to improve
our understanding of the mechanism underlying AIT. In this review, we focus on the critical issues related to the
clinical outcomes of CAR-based adoptive immunotherapy and discuss the rationales to refine this new cancer
therapeutic modality.
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Adoptive immunotherapy (AIT) using chimeric antigen
receptor-engineered T cells is a promising approach in
cancer treatment. Significant progresses made in the
past decades have contributed to the development of
more efficient antitumor immunotherapy. Incorporation
of a single chain variable fragment (scFv) of a tumor
antigen specific antibody and signaling domains of T cell
receptor (TCR) renders chimeric antigen receptor (CAR)
the specificity of antibody as well as the cytotoxicity of
cytotoxic T lymphocytes (CTLs) [1]. CAR endows T cells
antigen specific recognition, activation and proliferation
in an MHC independent manner. In addition, CAR
bypasses many mechanisms through which cancer cells
escape immunorecognition. These mechanisms include
down-regulation of the MHC, reduced expression of
costimulatory molecules, induction of suppressive cyto-
kines and recruitment of regulatory T cells. Besides these
beneficial effects, the technical feasibility of CAR makes it
even more attractive in the development of cancer adoptive* Correspondence: tianfang_li@rush.edu; shuangyinhan@zzu.edu.cn
†Equal contributors
3Rush University Medical Center, Chicago, IL 60612, USA
2Translational Research Center, Zhengzhou University People’s Hospital,
Zhengzhou, Henan 450003, China
Full list of author information is available at the end of the article
© 2013 Han et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orimmunotherapy. The observations from preclinical
and clinical studies have revealed a very encouraging
therapeutic efficacy of the CAR-mediated immunotherapy
in a variety of cancers including lymphoma, chronic
lymphocytic leukemia, melanoma, and neuroblastoma [2].
Although there are many obstacles needed to be overcome
before its widespread clinical use, it is still highly likely for
the CAR-based immunotherapy to become a mainstay in
clinical oncology field due to its improved tumoricidal ac-
tivity. In this review, we will briefly discuss the critical issues
related to the antitumor efficacy including the structure of
CAR, the potential of T cells subsets, the gene modification
of lymphocytes, the preconditioning regimens, etc.Promising results of clinical trials
The promising observations made from in vitro studies
and animal models have greatly encouraged physicians/
scientists to conduct clinical studies. The efficacy and
safety of adoptive CAR-engineered T cells have been
evaluated in multiple oncological settings. Currently,
about 30 ongoing clinical trials are under evaluation
(www.clinicaltrials.gov). Many advances have been reported
regarding the outcomes of these early clinical studies
(Phase I/II) including the effect on hematological ma-
lignancies and some solid tumors.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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been achieved from patients with chronic lymphocytic
leukemia (CLL) and lymphoma treated by CD19-orientated
CAR T cells [3]. CD19 is expressed on most types of B-cell
leukemia/lymphoma but absent in non-B lineage cells. Dr.
June and the colleagues have made significant contributions
that have greatly improved our understanding of the CAR
T cells. In one of their reports, 2 out of 3 refractory CLL
patients receiving CD19 CAR T cells therapy achieved
complete response (CR), and another patient demonstrated
partial response (PR) [4]. This proof of concept clinical
investigations have demonstrated an excellent cell en-
graftment (up to 3 log expansion) and tumor cell lysis,
eventually leading to complete remission. This pioneer
work inspired numerous clinical studies focusing on
CD19 for evaluating CAR technology. CD19 CAR studies
account for one third of ongoing clinical trials with
constantly increasing enrollments. Recent reports from
seven academic institutes showed 25% overall CR rate
(for review see [3,5,6]). In addition to CD19, other
molecules such as CD20, CD22, CD30 and CD33 have
also been tested for their potential as therapeutic targets
for hematological malignancies [7,8].
In parallel with the clinical trials in hematological
malignancies, CAR-based therapy has also been conducted
in solid tumors. CAR T cells targeting diasialoganglioside
(GD2) antigen and L1-cell adhesion molecule (L1CAM)
were generated for treatment of neuroblastoma [9]. Dr.
Louis and the colleagues generated the first-generation
CAR and modified the EBV-specific T cells. Enhanced
in vivo persistence and survival of the adoptively transferred
CAR-modified T cells resulted in a durable and complete
response in 3 out of 11 patients [10]. Dr. Lamers’ team
generated the CAR targeting carboxyl anhydrase IX
(CAIX) to treat metastatic renal cell carcinoma and
there was no objective clinical responses observed in
any of the treated patients [11]. In addition, CARs have
been generated against a number of surface molecules on
solid tumors, including HER2 for colorectal cancer [12],
folate receptor-α for ovarian cancer [13], carcinoembryonic
antigen (CEA) for colorectal and breast cancer [14], epi-
dermal growth factor receptor variant III (EGFRvIII) for
neuroblastoma [15], and prostate-specific membrane
antigen (PMSA) for prostate cancer [16]. Targeting solid
tumors is more challenging compared to the treatment
of hematological malignancies because of rare target anti-
gens, poor T cells trafficking to tumor site, less cytotoxicity
in local tumor immunosuppressive microenvironment.
Despite small sizes and different protocols, these phase
I/II studies did demonstrate the feasibility and safety of
CAR-based immunotherapy for the treatment of some
types of cancer. While adverse effects are generally toler-
able, the clinical efficacy of the first generation CAR is often
insufficient. The CARs of the second and third generationshave demonstrated improved efficacy and durable response,
which motivated scientists for dynamic and innovative
research in this field.
Evolving architecture of CAR
CARs have evolved considerably over the past decades.
Basically, CAR is comprised of an extracellular antigen-
binding moiety, a hinge and transmembrane (TM) domain,
and an intracellular signaling element. The initial CAR
of the first generation provides a proof of concept of the
targeting and activation of T cells. The CAR of the second
and third generations have been developed by addition of
dual or triple costimulatory signaling domains in order
to increase their cytotoxicity [17]. The most important
function of multiple signaling receptors is to enhance
signaling strength and persistence, subsequently increasing
in their overall potency.
Targeting, the first step for the redirected T lymphocytes
to function, is initiated at the single chain fragment variable
(scFv) region of extracellular domain. The scFv determines
the specificity of CAR and binds to target molecules
through a similar mechanism as antigen-antibody inter-
action. Many factors including the affinity of scFv, the
spatial topologic structure of epitopes, and antigen ex-
pression levels on tumor cells, have to be considered to
optimize the CAR-mediated T-cell response [18]. Besides
widely used scFv in many CARs, ligand or receptor can also
be used as targeting moiety because the corresponding
receptor or ligand are often overexpressed on tumor cells,
such as peptide against vascular endothelial growth factor
receptor (VEGFR) [19], and receptor for NKG2D [20]. The
potential immunogenicity of murine-derived scFv limits the
use of CAR in clinical setting. Utilizing humanized or fully
human antibodies to construct CAR may lower the im-
munogenicity and avoid immune-mediated recognition
leading to elimination of the genetically modified T cells.
A flexible hinge region between the targeting moiety and
the TM domain seems to be important for accessibility
to the epitope of the CAR-grafted T cells [21]. A study
performed by Dr. Guest demonstrated that a flexible hinge
region is needed for targeting membrane-proximal epitope,
instead of membrane-distal epitopes [22]. Considering the
spatial structure of the antigen, efficient antigen recognition
of CAR might be modulated by different choices of target
epitopes. Also, the TM domain is a pivotal region for CAR
function, more specifically, the oligomeric status of CARs.
Dr. Bridgeman and colleagues have demonstrated that
CAR containing a CD3ζ TM domain form homodimers
and are incorporated into the endogenous T cell receptor
(TCR) complex [23]. Various transmembrane regions have
been employed in CAR including those derived from
CD28, CD3z, CD8, CD4, FcRγ, etc.
Intracellular signaling domain is of vital importance for
CAR T cells to fulfill their antitumor function. Therefore,
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by adding the cytoplasmic domain of costimulatory re-
ceptors such as CD28, CD137 (4-1BB), CD134 (OX40),
or inducible costimulator (ICOS). Both in vitro and
in vivo studies have demonstrated that, in response to
the target antigen, the modified T cells with the second
or third generation CARs usually demonstrate sustained
proliferation, enhanced production of cytokines and tumor
lytic activity, and reduced activation-induced cell death. In
a study of mouse model for comparison of the first and
second generation CARs, Dr. Savoldo demonstrated the
greater persistence of T cells expressing a CD28/CD3ζ-
based CAR compared with T cells transduced by CAR with
CD3ζ signaling only [24]. The third generation CAR usually
shows better attributes of T cells than second generation
due to a synergistic effect of triple signaling domains [25].
Nowadays, most researchers prefer to use the second
generation CAR because of the concern about possible
signaling leakage of the third generation CAR due to
reduced activation threshold. As for costimulatory
molecules per se, we cannot reach a clear conclusion
about which one is better than the other. Previous ob-
servations indicate that inclusion of CD28 significantly
increases IL-2 production compared to the inclusion of
other molecules. The inclusion of CD137 may improve
survival, and the use of the ICOS signaling seems the
most efficient in target cell lysis [26-28].
Collectively, optimal designs of the CAR and a careful
choice of the tumor associate antigen (TAA) are indispens-
able for the CAR-mediated therapy to attain a significant
response. Although CARs in many clinical trials greatly
differ in their configurations, comprehensive comparisons
are still lacking. With the clinical results in mind, we need
to attain a better understanding of optimal CAR signaling
to promote sustained T-cell function and survival, to avoid
undue proliferation, and to prevent premature death and
rapid exhaustion. It is also desirable to add more elements
such as homing and suicide genes to improve their func-
tionality. It is imperative to develop a more competent and
safer architecture of CAR, so-called the fourth generation
CAR. Optimized design of the new generation CAR may
be achieved by more extensive basic studies investigating
the spatiotemporal dynamics of CAR-mediated molecular
events and unraveling the molecular basis of T-cell ac-
tivation by CARs.
Therapeutic potential of T cell subsets
In the past decades, researchers have tried to generate
sufficient quantity of antigen-specific T cells based on the
notion that the absolute number of transferred T cells is
correlated with tumor responses. Most clinical trials take
use of mixed populations of CD3+ T cells containing
antigen-specific CD8+ and CD4+ T cells, and the pheno-
typic and functional attributes of the transferred T cellsare subject to natural variation. As the heterogeneity and
potential variable of polyclonal unselected cells could
affect the efficacy and safety of cancer immunotherapy,
precise detection and careful selection of the potentially
most potent T cell subsets would increase their adoptive
transfer efficiency.
It becomes increasingly clear that adoptive transfer of
the less-differentiated T cell subsets is associated with
superior T cell engraftment, persistence, and antitumor
immunity, thus highly correlating with objective clinical
responses [29]. An in vivo study demonstrated that adop-
tive transfer of central memory T cells (TCM) induced
complete responses at the tested cell dose, whereas the
mice in group of receiving effector memory T cells (TEM)
suffered uncontrolled tumor growth [30]. This difference
can be deciphered by the fact that TCM cells can self-renew
and differentiate into effector T cells in vivo, while TEM cells
have lost this plasticity. Subsequently, a subset of stem cell
memory T cell (TSCM) has been demonstrated to have su-
perior ability to mediate cancer regression compared to the
TCM and TEM populations [31]. Therefore, ex vivo sorting/
selection for superior T cell subsets like TCM or TSCM cells
prior to adoptive transfer and/or gene transfer could im-
prove in vivo persistence and therapeutic efficacy. Clinical
trials have been conducting to evaluate the potential of the
T cell subsets from the peripheral blood [32].
Many strategies have been utilized to obtain sufficient
numbers of defined therapeutically clinical-grade CTL ef-
fectors. Current protocol includes isolation and activation
using agonistic antibodies CD3 or γ-irradiated allogeneic
peripheral blood mononuclear cell (PBMC) vs EBV-
transformed B lymphoblastoid cell line (LCL) feeders,
and a subsequent rapid expansion of cells in the presence
of IL-2. Since ex vivo expansion inevitably drives T cell dif-
ferentiation and results in the loss of in vivo antitumor effi-
cacy, new strategies for handling cultured T cells have been
developing recently. Traditional method for cell processing
has been replaced by the automated manufacturing system.
Activation of T cells can be induced by various kinds of
antigen-non-specific artificial APCs (aAPCs) such as mag-
netic CD3/CD28 beads and K32 cell line (CD32-transfected
precursor K562 chronic erythroleukemic cell line) [33].
IL-2 has been used for long time for T cell expansion.
Recent evidence suggests that IL-2 may have some negative
effects by depleting memory T cells and increasing the
number of tumor protecting regulatory T cells (Tregs) [34].
In contrast, IL-15 can increase the persistence of CD8+
memory T lymphocytes, prevent Fas induced apoptosis and
overcome tolerance of tumor specific CD8+ T cells [35].
The expansion of naive CD8+ T cells in the presence of
IL-15 generates cells with the phenotypic and functional
properties of naturally occurring TCM with superior
antitumor capability. Therapeutic potentials of small mo-
lecular modulators in critical metabolic and developmental
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evaluated including those in the PI3K-AKT-mTOR and
Wnt-β-catenin pathways [36].
Our understanding of the fundamental properties of
heterogeneous subsets of T cells keep improving and
mounting evidence indicates that selection of defined
populations for gene modification is necessary to maximize
the outcome of adoptive immunotherapy for cancer.
The phenotypic and functional diversity of the genetically
modified T cells may provide opportunities to enhance
cancer immunotherapy. Because of severe adverse events
reported in CAR clinical trial, it may become requisite to
choose the defined T cell subsets in context of clinical
setting. With recent advent of cell bioprocessing and
genetic engineering technology, it is now possible to
generate tumor-reactive CD8+ T cells of a defined subset.
The in-depth understanding of phenotypes and functions
of T cell subsets will have profound impact on future CAR
T cell therapy.
Improved methods of T cell gene modification
CAR-based immunotherapy is dependent on the efficient
genetic modifications of the infused T cells. Since extensive
ex vivo T cell expansion is prerequisite for adoptive cell
transfer, genetic modifications must be stable and require
vector integration. For this reason, transduction using
chromosome-integrating vectors like retroviruses or lentivi-
ruses is superior to transfection with transient gene expres-
sion of DNA in genetically modified T cell therapy.
To date, most studies of CAR-related therapy utilize
retroviruses or lentiviruses for gene delivery. Data from
several sources indicate that retroviral vectors do not
elicit clinically significant genotoxicity when used to deliver
therapeutic genes to T cells [37]. Dr. Scholler reported
long-term results from three clinical trials to evaluate retro-
viral vector–engineered T cells. In a clinical analysis of HIV
and malignancy, which included over 200 patients with the
follow-ups for as long as 11 years, transduced T cells
were detected in 98% of patients with no evidence of
integration-induced immortalization [38]. Lentivirus
vectors have some advantages over retroviral vectors as
they can transduce non-dividing cells. In addition, lentiviral
vectors have higher cargo capacity and reduced suscep-
tibility to gene silencing. Because of its safety profile, it
is expected that the future use of lentiviral vectors will
keep increasing [39]. Besides, Ad5/F35 adenoviral vector
transduction were reported to mediate gene transfer in up
to 10% of resting T cells and 30–45% of T cells after acti-
vation with phyto-haemagglutinin. Ad5/F35 vectors hold
promise for adoptive transfer of engineered lymphocytes
in clinical situations where expression of a transgene for
less than a week is required [40].
Along with the advance of viral vectors, non-viral gene
transduction systems have been developed for clinicaltrials as well. The lower costs and better safety profile
of non-viral vectors have attracted much attention.
Transposon-based system is one of the promising methods
because of much higher efficiency of the transgene inte-
gration. Sleeping Beauty was the first transposon system
used for modification of human T lymphocytes and dem-
onstrated stable expression of CAR with killing of targeted
cancer cells in vitro as well as in animal models [41].
PiggyBac transposons mediate stable gene expression in
about 20% of primary T cells before selection, and the
rate was increased to 40% after selection. The expres-
sion can sustain for over 9 weeks in culture through
multiple logs of expansion [42]. Thus far, both Sleeping
Beauty and PiggyBac have been used for gene modifi-
cation of human T cells with CAR for HER2, CD19 and
so on. RNA-based electroporation of lymphocytes is
also an attractive approach because of the almost 100%
transduction efficiencies, less genotoxic and transient
expression [43]. The clinical trial was planned to treat
the hematological malignancies.
While genetic-modification strategies provide us with
the opportunity to harness the immune system against
malignant disease, several issues must be taken into con-
sideration when selecting the technology used to engineer
cellular immunity. These factors include the size, number,
and expression level of the transgenes, the requirement
for permanent or transient genetic modification, and differ-
ent delivery approaches for either constitutive or inducible
transgene expression.
Optimizing regimen of host preconditioning
Numerous animal experiments as well as clinical studies in
humans strongly suggest that the effectiveness of adoptively
transferred T cells can be reinforced when combined with
conventional cytotoxic agents such as cyclophosphamide
and fludarabine, and occasionally concomitantly used
with a low-dose irradiation. It was observed in adop-
tive transfer of tumor infiltrated lymphocytes (TILs)
that preconditioning with systemic non-myeloablative
chemotherapy can induce clear and reproducible responses
in a substantial percentage (~50%) of patients [44]. There-
fore, most recent clinical trials using CAR-engineered
T cells incorporate a lymphodepletion step, which has
demonstrated an increased antitumor response [45,46].
Clearly, preconditioning chemotherapy plays a critical
role in the efficacy of targeted T-cell therapy.
Several mechanisms may contribute to the increased
efficacy of Tcell-based immunotherapy in the lymphopaenic
environment. Deletion of the suppressive CD4+CD25+ regu-
latory T (TReg) cells in preconditioning recipient will help
the infused T cells to function normally [47]. Competition
for the limited amount of the cytokines (so-called cytokine
sink) between transferred and endogenous T cells interferes
CD8+ T cell homeostasis. Preconditioning will eliminate
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infused cells [48]. Transient eradication of endogenous
lymphocytes might cause necrosis or apoptosis of tumor
cells, which results in antigen presenting cells uptake of
tumor antigens and the subsequent cross-presentation
of these antigens to the adoptively transferred tumor-
reactive CD8+ T cells [49].
The improved effectiveness of immunotherapy following
a non-myeloablative lymphodepleting regimen encourages
the researchers for more elegant conditioning regimens in
selective or intensive ways. TReg cells might be selectively
depleted with directed immunotoxins or suppressed by
administering a cytokine such as tumor necrosis factor
(TNF). Exogenous replenishment of certain cytokines
may alleviate the sink effect coming from the endogenous
T cells. Attempt of using cytokines such as IL-7, IL-15 and
IL-21 might avoid suppressive function of IL-2 toward
TReg cells. Intensive myeloablative preconditioning regimen
with chemotherapy, total body irradiation and human stem
cell transplantation (HSCT) is also under planned in
human AIT protocol.
Conclusions and perspectives
CAR-modified T cells constitute a very appealing approach
to cancer immunotherapy. Despite the promising results
obtained from numerous clinical trials following the
infusion of CAR-modified T cells, some severe adverse
reactions were reported [12,50,51]. Recent reports have
highlighted some key issues and future directions to
avoid these adverse events. Care selection of candidate
target antigens is essential for improved efficacy and
safety of the CAR-based therapy. Additional factors
needed to be considered include the density of target
molecules, accessibility of the epitope, affinity of the
scFv, flexibility of hinge, property of the signaling, etc.
New elements are being evaluated including a control-
lable suicide gene like caspase 9 or HSV-TK as a safety
switch [52], and a chemokine receptor for T cells to
migrate to tumor site. Furthermore, the best sources of
the selective T cell populations are getting attention for
CAR T cell therapy. Many factors may contribute to
the improved quality of the cells such as closed cell
processing system, new activation/expansion methods,
selection of T cell subsets with therapeutic potentials,
improved culture condition, etc. Current protocols for
cell bioengineering need to be simplified to facilitate
widespread application of such treatment strategy. Finally,
because it is technically challenging, labor intensive and
very costly, most of the studies have been conducted
in academic centers. Future work needs collective effort
from regulatory organizations, biological companies,
medical centers and academic institutions. We believe
these collaborations, some of which are already in progress,
would lead to the development of the comprehensiveapproaches to maximize the efficacy of the cancer
immunotherapy.
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